Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Total 13F shares
-
4,675,016
-
Share change
-
+264,988
-
Total reported value
-
$21,738,469
-
Price per share
-
$4.65
-
Number of holders
-
32
-
Value change
-
+$1,170,257
-
Number of buys
-
19
-
Number of sells
-
4
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2017
As of 31 Dec 2017,
Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,675,016 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, Vanguard Group Inc, BlackRock Inc., Artal Group S.A., BRIDGEWAY CAPITAL MANAGEMENT INC, NORTHERN TRUST CORP, Destination Wealth Management, GEODE CAPITAL MANAGEMENT, LLC, Bank of New York Mellon Corp, and MORGAN STANLEY.
This page lists
32
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.